Piper Sandler Maintains Neutral on Medtronic, Lowers Price Target to $91

Benzinga Newsdesk www.benzinga.com Negative 77.7%

Neg 77.7% Neu 0% Pos 0%

Piper Sandler analyst Matt O'Brien maintains Medtronic (NYSE:MDT) with a Neutral and lowers the price target from $105 to $91.